Vascular Endothelial Growth Factor in the Circulation in Cancer Patients May Not Be a Relevant Biomarker
Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypot...
Gespeichert in:
| Veröffentlicht in: | PloS one Jg. 6; H. 5; S. e19873 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Public Library of Science
26.05.2011
Public Library of Science (PLoS) |
| Schlagworte: | |
| ISSN: | 1932-6203, 1932-6203 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that "true" circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis.
We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10(6), non-RCC: 6.2 IU/10(6) platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration.
Our findings suggest that "true" freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. |
|---|---|
| AbstractList | Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that "true" circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis. We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10.sup.6, non-RCC: 6.2 IU/10.sup.6 platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration. Our findings suggest that "true" freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. Background Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that "true" circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis. Methodology We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10.sup.6, non-RCC: 6.2 IU/10.sup.6 platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration. Conclusions Our findings suggest that "true" freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that "true" circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis.BACKGROUNDLevels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that "true" circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis.We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10(6), non-RCC: 6.2 IU/10(6) platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration.METHODOLOGYWe determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10(6), non-RCC: 6.2 IU/10(6) platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration.Our findings suggest that "true" freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer.CONCLUSIONSOur findings suggest that "true" freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. BACKGROUND: Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that "true" circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis. METHODOLOGY: We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10(6), non-RCC: 6.2 IU/10(6) platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration. CONCLUSIONS: Our findings suggest that "true" freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. Background Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that “true” circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis. Methodology We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/106, non-RCC: 6.2 IU/106 platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration. Conclusions Our findings suggest that “true” freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that "true" circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis. We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/10(6), non-RCC: 6.2 IU/10(6) platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration. Our findings suggest that "true" freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. Background Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose, non-standardized measurements in plasma and serum were used, without correction for artificial VEGF release by platelets activated ex vivo. We hypothesize that “true” circulating (c)VEGF levels in most cancer patients are low and unrelated to cancer load or tumour angiogenesis. Methodology We determined VEGF levels in PECT, a medium that contains platelet activation inhibitors, in citrate plasma, and in isolated platelets in 16 healthy subjects, 18 patients with metastatic non-renal cancer (non-RCC) and 12 patients with renal cell carcinoma (RCC). In non-RCC patients, circulating plasma VEGF levels were low and similar to VEGF levels in controls if platelet activation was minimized during the harvest procedure by PECT medium. In citrate plasma, VEGF levels were elevated in non-RCC patients, but this could be explained by a combination of increased platelet activation during blood harvesting, and by a two-fold increase in VEGF content of individual platelets (controls: 3.4 IU/106, non-RCC: 6.2 IU/106 platelets, p = 0.001). In contrast, cVEGF levels in RCC patients were elevated (PECT plasma: 64 pg/ml vs. 21 pg/ml, RCC vs. non-RCC, p<0.0001), and not related to platelet VEGF concentration. Conclusions Our findings suggest that “true” freely cVEGF levels are not elevated in the majority of cancer patients. Previously reported elevated plasma VEGF levels in cancer appear to be due to artificial release from activated platelets, which in cancer have an increased VEGF content, during the blood harvest procedure. Only in patients with RCC, which is characterized by excessive VEGF production due to a specific genetic defect, were cVEGF levels elevated. This observation may be related to limited and selective success of anti-VEGF agents, such as bevacizumab and sorafenib, as monotherapy in RCC compared to other forms of cancer. |
| Audience | Academic |
| Author | Meijers, Joost C. M. Niers, Tatjana M. H. Richel, Dick J. Schlingemann, Reinier O. |
| AuthorAffiliation | 2 Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands 1 Department of Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands University of Hong Kong, Hong Kong 3 Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands |
| AuthorAffiliation_xml | – name: University of Hong Kong, Hong Kong – name: 3 Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands – name: 2 Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands – name: 1 Department of Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands |
| Author_xml | – sequence: 1 givenname: Tatjana M. H. surname: Niers fullname: Niers, Tatjana M. H. – sequence: 2 givenname: Dick J. surname: Richel fullname: Richel, Dick J. – sequence: 3 givenname: Joost C. M. surname: Meijers fullname: Meijers, Joost C. M. – sequence: 4 givenname: Reinier O. surname: Schlingemann fullname: Schlingemann, Reinier O. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21637343$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk11v0zAUhiM0xD7gHyCIhATioiX-SOJwgTSqbVQaDA3YrXXiOI07Ny62M9i_x1lT1EwTQr6wc_yc1_abcw6jvda0Moqeo2SKSI7eLU1nW9DTdQhPkwQVLCePogNUEDzJcEL2dtb70aFzyyRJCcuyJ9E-RhnJCSUHUXMFTnQabHzSVsY3UivQ8Zk1v3wTn4LwxsaqjcNGPFO2J70ybR-aQSukjb-GgGy9iz_DbfzF-PijjCG-lFreQBu-lFmBvZb2afS4Bu3ks2E-in6cnnyffZqcX5zNZ8fnE5EVyE8YqTFksiSsqsucIVbQFJeMYJZkKA9Tios6JzWhgmKocCpKEDihkkGBKQJyFL3c6K61cXwwyXGEC0YISkkWiPmGqAws-dqqcMFbbkDxu4CxCw7WK6ElT4FCUYpaiKSkVUrLtBCI0hzyEjASLGh9GE7rypWsRHDCgh6Jjnda1fCFueEEJTjLSBB4MwhY87OTzvOVckJqDa00neMsT3D4ixkK5Kt75MOPG6gFhPurtjbhWNFr8mOaZ4wVKcKBmj5AhVHJlRKhoGoV4qOEt6OEwHj52y-gc47Pv13-P3txNWZf77CNBO0bZ3TXF5kbgy92jf7r8LaSA_B-AwhrnLOy5kL5u2INT1Oao4T3bbM1jfdtw4e2Ccn0XvJW_59pfwAmDRqY |
| CitedBy_id | crossref_primary_10_48095_cccu2013034 crossref_primary_10_3390_cancers16223857 crossref_primary_10_1097_MCG_0b013e318236effa crossref_primary_10_3389_fpsyt_2021_780095 crossref_primary_10_1038_bjc_2016_275 crossref_primary_10_1080_14737159_2025_2518134 crossref_primary_10_1002_hep_27747 crossref_primary_10_1093_jjco_hyv102 crossref_primary_10_1093_neuonc_not226 crossref_primary_10_1080_02713683_2017_1403632 crossref_primary_10_1186_1752_0509_5_193 crossref_primary_10_5301_JBM_2012_8989 crossref_primary_10_1371_journal_pone_0145375 crossref_primary_10_1007_s10585_012_9496_y crossref_primary_10_2337_dc12_1951 crossref_primary_10_4155_bio_13_322 crossref_primary_10_1111_aos_12081 crossref_primary_10_1016_j_urolonc_2013_07_011 crossref_primary_10_1038_s41598_018_34506_4 crossref_primary_10_1089_dna_2013_2249 crossref_primary_10_1182_blood_2012_04_423079 crossref_primary_10_1586_17512433_2014_884458 crossref_primary_10_1097_JTO_0b013e31823f45c1 crossref_primary_10_1369_00221554221115767 crossref_primary_10_1016_j_preteyeres_2018_10_006 crossref_primary_10_1111_cas_12097 crossref_primary_10_3892_etm_2012_594 crossref_primary_10_1186_1756_0500_7_369 crossref_primary_10_4251_wjgo_v9_i1_42 crossref_primary_10_7759_cureus_15303 crossref_primary_10_1155_2013_289563 crossref_primary_10_1186_s40880_016_0084_4 |
| Cites_doi | 10.1097/PPO.0b013e318178d9de 10.1073/pnas.93.20.10589 10.1073/pnas.94.2.663 10.1038/bjc.1998.158 10.1177/002215540205000603 10.1073/pnas.93.20.10595 10.1056/NEJM199512283332608 10.1200/JCO.2005.01.186 10.1042/BST0360472 10.1023/B:AGEN.0000029415.62384.ba 10.1634/theoncologist.3-2-0 10.1016/j.yexcr.2005.11.012 10.1016/S1350-9462(02)00043-5 10.1038/sj.bjc.6690437 10.1182/blood.V96.13.4216 10.1200/JCO.1999.17.8.2530 10.1016/S0304-3835(99)00426-7 10.1128/MCB.17.9.5629 10.1080/07853890410026098 10.1006/scbi.1998.0091 10.1006/cyto.1997.0297 10.1182/blood.V57.2.199.199 10.1080/00365510260296492 10.1182/blood-2008-06-159541 10.1016/S0959-8049(98)00282-2 10.1038/sj.cdd.4402313 10.1054/bjoc.1999.1033 10.1159/000012095 10.1007/s00280-006-0403-6 10.1056/NEJMoa021491 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2011 Public Library of Science 2011 Niers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Niers et al. 2011 |
| Copyright_xml | – notice: COPYRIGHT 2011 Public Library of Science – notice: 2011 Niers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Niers et al. 2011 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0019873 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Collection (ProQuest) ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest One Academic ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine |
| DocumentTitleAlternate | Questions cVEGF in Cancer |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1298331536 oai_doaj_org_article_5a4a9bcfcc0b4d54b59c1447a7ba21c8 PMC3102663 2898990391 A476889512 21637343 10_1371_journal_pone_0019873 |
| Genre | Journal Article |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PYCSY RIG RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM ALIPV CGR CUY CVF ECM EIF NPM PV9 RZL BBORY 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c691t-83f2a6eb38dfb78189452b83280617328529f73f34c42ad25cbac204e8a9241a3 |
| IEDL.DBID | FPL |
| ISICitedReferencesCount | 38 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000291052200017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Sun Jun 04 06:36:42 EDT 2023 Tue Oct 14 18:57:38 EDT 2025 Tue Nov 04 01:57:06 EST 2025 Fri Sep 05 11:55:18 EDT 2025 Sat Nov 29 14:22:29 EST 2025 Sat Nov 29 13:15:12 EST 2025 Sat Nov 29 10:02:37 EST 2025 Wed Nov 26 09:23:51 EST 2025 Wed Nov 26 09:26:37 EST 2025 Thu May 22 21:21:18 EDT 2025 Mon Jul 21 05:28:01 EDT 2025 Tue Nov 18 21:45:38 EST 2025 Sat Nov 29 02:49:38 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c691t-83f2a6eb38dfb78189452b83280617328529f73f34c42ad25cbac204e8a9241a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceived and designed the experiments: ROS JCMM DJR. Performed the experiments: JCMM TMN. Analyzed the data: ROS JCMM DJR TMN. Contributed reagents/materials/analysis tools: JCMM DJR. Wrote the paper: ROS JCMM DJR TMN. |
| OpenAccessLink | http://dx.doi.org/10.1371/journal.pone.0019873 |
| PMID | 21637343 |
| PQID | 1298331536 |
| PQPubID | 1436336 |
| PageCount | e19873 |
| ParticipantIDs | plos_journals_1298331536 doaj_primary_oai_doaj_org_article_5a4a9bcfcc0b4d54b59c1447a7ba21c8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3102663 proquest_miscellaneous_870293261 proquest_journals_1298331536 gale_infotracmisc_A476889512 gale_infotracacademiconefile_A476889512 gale_incontextgauss_ISR_A476889512 gale_incontextgauss_IOV_A476889512 gale_healthsolutions_A476889512 pubmed_primary_21637343 crossref_citationtrail_10_1371_journal_pone_0019873 crossref_primary_10_1371_journal_pone_0019873 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-05-26 |
| PublicationDateYYYYMMDD | 2011-05-26 |
| PublicationDate_xml | – month: 05 year: 2011 text: 2011-05-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2011 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | M Shibuya (ref3) 2006; 312 R Salgado (ref12) 1999; 80 K Werther (ref25) 2002; 62 NJ Webb (ref8) 1998; 10 A Grothey (ref34) 2008; 14 P Salven (ref27) 1999; 5 HM Verheul (ref30) 2000; 6 R Mohle (ref4) 1997; 94 YH Kusumanto (ref26) 2003; 6 MM Davies (ref14) 2000; 82 AN Witmer (ref10) 2002; 50 J Folkman (ref1) 1995; 333 E Gunsilius (ref7) 2000; 58 JR Gnarra (ref16) 1996; 93 KL Kaplan (ref22) 1981; 57 GJ Caine (ref24) 2004; 36 HM Verheul (ref28) 1998; 3 GL Klement (ref35) 2009; 113 HM Verheul (ref29) 2000; 96 RE Banks (ref5) 1998; 77 ML George (ref36) 2000; 6 T Yoshikawa (ref15) 2000; 153 LG Presta (ref32) 1997; 57 O Iliopoulos (ref17) 1996; 93 R Longo (ref11) 2007; 60 D Mukhopadhyay (ref18) 1997; 17 MJ Nyhan (ref20) 2008; 36 BI Rini (ref31) 2005; 23 T Veikkola (ref2) 1999; 9 HM Verheul (ref6) 1997; 3 I Hyodo (ref13) 1998; 34 RJ Motzer (ref21) 1999; 17 JC Yang (ref33) 2003; 349 KL Kaplan (ref23) 1986; 5 PP Kapitsinou (ref19) 2008; 15 AN Witmer (ref9) 2003; 22 11110694 - Blood. 2000 Dec 15;96(13):4216-21 12890841 - N Engl J Med. 2003 Jul 31;349(5):427-34 10737380 - Br J Cancer. 2000 Mar;82(5):1004-8 9271438 - Mol Cell Biol. 1997 Sep;17(9):5629-39 18481984 - Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8 9617569 - Cytokine. 1998 Apr;10(4):254-7 19036702 - Blood. 2009 Mar 19;113(12):2835-42 10360671 - Br J Cancer. 1999 May;80(5-6):892-7 18219317 - Cell Death Differ. 2008 Apr;15(4):650-9 10705245 - Oncology. 2000 Feb;58(2):169-74 10100697 - Clin Cancer Res. 1999 Mar;5(3):487-91 16336962 - Exp Cell Res. 2006 Mar 10;312(5):549-60 12019293 - J Histochem Cytochem. 2002 Jun;50(6):767-77 8855222 - Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10589-94 9528841 - Br J Cancer. 1998 Mar;77(6):956-64 17370072 - Cancer Chemother Pharmacol. 2007 Jul;60(2):151-70 15224653 - Ann Med. 2004;36(4):273-7 12597922 - Prog Retin Eye Res. 2003 Jan;22(1):1-29 10779624 - Cancer Lett. 2000 May 29;153(1-2):7-12 6160890 - Blood. 1981 Feb;57(2):199-202 9012841 - Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 7491141 - N Engl J Med. 1995 Dec 28;333(26):1757-63 10070308 - Eur J Cancer. 1998 Dec;34(13):2041-5 18536556 - Cancer J. 2008 May-Jun;14(3):170-7 2427239 - Crit Rev Oncol Hematol. 1986;5(3):235-55 10955796 - Clin Cancer Res. 2000 Aug;6(8):3147-52 10656446 - Clin Cancer Res. 2000 Jan;6(1):166-71 8855223 - Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9 10388096 - Oncologist. 1998;3(2):II 15166496 - Angiogenesis. 2003;6(4):283-7 12387579 - Scand J Clin Lab Invest. 2002;62(5):343-50 10561319 - J Clin Oncol. 1999 Aug;17(8):2530-40 9815613 - Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 9377574 - Cancer Res. 1997 Oct 15;57(20):4593-9 15534359 - J Clin Oncol. 2005 Feb 10;23(5):1028-43 10343072 - Semin Cancer Biol. 1999 Jun;9(3):211-20 |
| References_xml | – volume: 14 start-page: 170 issue: 3 year: 2008 ident: ref34 article-title: Targeting angiogenesis driven by endothelial growth factors using antibody based therapy. publication-title: Cancer Journal doi: 10.1097/PPO.0b013e318178d9de – volume: 93 start-page: 10589 year: 1996 ident: ref16 article-title: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. publication-title: Proc.Natl.Acad.Sci.U.S.A doi: 10.1073/pnas.93.20.10589 – volume: 94 start-page: 663 year: 1997 ident: ref4 article-title: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. publication-title: Proc.Natl.Acad.Sci.U.S.A doi: 10.1073/pnas.94.2.663 – volume: 77 start-page: 956 year: 1998 ident: ref5 article-title: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. publication-title: Br.J.Cancer doi: 10.1038/bjc.1998.158 – volume: 50 start-page: 767 issue: 6 year: 2002 ident: ref10 article-title: Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. publication-title: J.Histochem.Cytochem doi: 10.1177/002215540205000603 – volume: 57 start-page: 4593 year: 1997 ident: ref32 article-title: Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res – volume: 93 start-page: 10595 year: 1996 ident: ref17 article-title: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. publication-title: Proc.Natl.Acad.Sci.U.S.A doi: 10.1073/pnas.93.20.10595 – volume: 5 start-page: 487 year: 1999 ident: ref27 article-title: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. publication-title: Clin Cancer Res – volume: 333 start-page: 1757 year: 1995 ident: ref1 article-title: Seminars in Medicine of the Beth Israel Hospital,Boston. Clinical applications of research on angiogenesis. publication-title: N.Engl.J.Med doi: 10.1056/NEJM199512283332608 – volume: 23 start-page: 1028 issue: 5 year: 2005 ident: ref31 article-title: Biology and clinical development of vascular endothelial growth factor targeted therapy in renal cell carcinoma. publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.186 – volume: 36 start-page: 472 year: 2008 ident: ref20 article-title: Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. publication-title: Biochemical Society transactions doi: 10.1042/BST0360472 – volume: 6 start-page: 283 year: 2003 ident: ref26 article-title: Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. publication-title: Angiogenesis doi: 10.1023/B:AGEN.0000029415.62384.ba – volume: 3 issue: 2 year: 1998 ident: ref28 article-title: Tumor Growth: A Putative Role for Platelets? publication-title: Oncologist doi: 10.1634/theoncologist.3-2-0 – volume: 312 start-page: 549 year: 2006 ident: ref3 article-title: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. publication-title: Exp.Cell Res doi: 10.1016/j.yexcr.2005.11.012 – volume: 22 start-page: 1 year: 2003 ident: ref9 article-title: Vascular endothelial growth factors and angiogenesis in eye disease. publication-title: Prog.Retin.Eye Res doi: 10.1016/S1350-9462(02)00043-5 – volume: 80 start-page: 892 year: 1999 ident: ref12 article-title: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. publication-title: Br.J.Cancer doi: 10.1038/sj.bjc.6690437 – volume: 96 start-page: 4216 year: 2000 ident: ref29 article-title: Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. publication-title: Blood doi: 10.1182/blood.V96.13.4216 – volume: 17 start-page: 2530 year: 1999 ident: ref21 article-title: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. publication-title: J.Clin.Oncol doi: 10.1200/JCO.1999.17.8.2530 – volume: 153 start-page: 7 year: 2000 ident: ref15 article-title: Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. publication-title: Cancer Lett doi: 10.1016/S0304-3835(99)00426-7 – volume: 17 start-page: 5629 year: 1997 ident: ref18 article-title: The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. publication-title: Mol.Cell Biol doi: 10.1128/MCB.17.9.5629 – volume: 36 start-page: 273 year: 2004 ident: ref24 article-title: Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. publication-title: Ann. Med doi: 10.1080/07853890410026098 – volume: 5 start-page: 235 issue: 3 year: 1986 ident: ref23 article-title: Plasma Levels of platelet secretory proteins. Crit Rev Oncol. publication-title: Hematol – volume: 9 start-page: 211 year: 1999 ident: ref2 article-title: VEGFs, receptors and angiogenesis. publication-title: Semin.Cancer Biol doi: 10.1006/scbi.1998.0091 – volume: 6 start-page: 166 year: 2000 ident: ref30 article-title: Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. publication-title: Clin.Cancer Res – volume: 10 start-page: 254 year: 1998 ident: ref8 article-title: Activated human neutrophils express vascular endothelial growth factor (VEGF). publication-title: Cytokine doi: 10.1006/cyto.1997.0297 – volume: 57 start-page: 199 year: 1981 ident: ref22 article-title: Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. publication-title: Blood doi: 10.1182/blood.V57.2.199.199 – volume: 62 start-page: 343 year: 2002 ident: ref25 article-title: Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. publication-title: Scand. J. Clin. Lab Invest doi: 10.1080/00365510260296492 – volume: 113 start-page: 2835 issue: 12 year: 2009 ident: ref35 article-title: Platelets actively sequester angiogenesis regulators. publication-title: Blood doi: 10.1182/blood-2008-06-159541 – volume: 34 start-page: 2041 year: 1998 ident: ref13 article-title: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. publication-title: Eur.J.Cancer doi: 10.1016/S0959-8049(98)00282-2 – volume: 15 start-page: 650 year: 2008 ident: ref19 article-title: The VHL tumor suppressor and HIF; insights from genetic studies in mice. publication-title: Cell Death and differentiation doi: 10.1038/sj.cdd.4402313 – volume: 82 start-page: 1004 year: 2000 ident: ref14 article-title: Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume. publication-title: Br. J. Cancer doi: 10.1054/bjoc.1999.1033 – volume: 6 start-page: 3147 year: 2000 ident: ref36 article-title: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? publication-title: Clin.Cancer Res – volume: 3 start-page: 2187 year: 1997 ident: ref6 article-title: Platelet: transporter of vascular endothelial growth factor. publication-title: Clin.Cancer Res – volume: 58 start-page: 169 year: 2000 ident: ref7 article-title: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. publication-title: Oncology doi: 10.1159/000012095 – volume: 60 start-page: 151 year: 2007 ident: ref11 article-title: Challenges for patient selection with VEGF inhibitors. publication-title: Cancer Chemother.Pharmacol doi: 10.1007/s00280-006-0403-6 – volume: 349 start-page: 427 year: 2003 ident: ref33 article-title: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. publication-title: N Engl J Med: doi: 10.1056/NEJMoa021491 – reference: 10737380 - Br J Cancer. 2000 Mar;82(5):1004-8 – reference: 9271438 - Mol Cell Biol. 1997 Sep;17(9):5629-39 – reference: 12387579 - Scand J Clin Lab Invest. 2002;62(5):343-50 – reference: 10705245 - Oncology. 2000 Feb;58(2):169-74 – reference: 8855222 - Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10589-94 – reference: 12597922 - Prog Retin Eye Res. 2003 Jan;22(1):1-29 – reference: 8855223 - Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9 – reference: 10388096 - Oncologist. 1998;3(2):II – reference: 18481984 - Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8 – reference: 9815613 - Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 – reference: 15224653 - Ann Med. 2004;36(4):273-7 – reference: 9528841 - Br J Cancer. 1998 Mar;77(6):956-64 – reference: 12019293 - J Histochem Cytochem. 2002 Jun;50(6):767-77 – reference: 10360671 - Br J Cancer. 1999 May;80(5-6):892-7 – reference: 6160890 - Blood. 1981 Feb;57(2):199-202 – reference: 10343072 - Semin Cancer Biol. 1999 Jun;9(3):211-20 – reference: 10070308 - Eur J Cancer. 1998 Dec;34(13):2041-5 – reference: 9617569 - Cytokine. 1998 Apr;10(4):254-7 – reference: 19036702 - Blood. 2009 Mar 19;113(12):2835-42 – reference: 7491141 - N Engl J Med. 1995 Dec 28;333(26):1757-63 – reference: 18536556 - Cancer J. 2008 May-Jun;14(3):170-7 – reference: 17370072 - Cancer Chemother Pharmacol. 2007 Jul;60(2):151-70 – reference: 9377574 - Cancer Res. 1997 Oct 15;57(20):4593-9 – reference: 10561319 - J Clin Oncol. 1999 Aug;17(8):2530-40 – reference: 10779624 - Cancer Lett. 2000 May 29;153(1-2):7-12 – reference: 12890841 - N Engl J Med. 2003 Jul 31;349(5):427-34 – reference: 10100697 - Clin Cancer Res. 1999 Mar;5(3):487-91 – reference: 10955796 - Clin Cancer Res. 2000 Aug;6(8):3147-52 – reference: 2427239 - Crit Rev Oncol Hematol. 1986;5(3):235-55 – reference: 10656446 - Clin Cancer Res. 2000 Jan;6(1):166-71 – reference: 11110694 - Blood. 2000 Dec 15;96(13):4216-21 – reference: 9012841 - Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 – reference: 16336962 - Exp Cell Res. 2006 Mar 10;312(5):549-60 – reference: 15166496 - Angiogenesis. 2003;6(4):283-7 – reference: 18219317 - Cell Death Differ. 2008 Apr;15(4):650-9 – reference: 15534359 - J Clin Oncol. 2005 Feb 10;23(5):1028-43 |
| SSID | ssj0053866 |
| Score | 2.216644 |
| Snippet | Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this purpose,... Background Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this... BACKGROUND: Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this... Background Levels of circulating vascular endothelial growth factor (VEGF) have widely been used as biomarker for angiogenic activity in cancer. For this... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e19873 |
| SubjectTerms | Activation Aged Angiogenesis Background levels Baseline studies beta-Thromboglobulin - metabolism Bevacizumab Biomarkers Biomarkers, Tumor - blood Blood Blood platelets Blood Platelets - metabolism Cancer Cancer metastasis Cancer patients Care and treatment Case-Control Studies Citric acid Colorectal cancer Granulocytes Humans Kidney cancer Medicine Metastases Metastasis Middle Aged Monoclonal antibodies Neoplasms - blood Neoplasms - physiopathology Neutrophils Patients Platelet Activation Platelet Factor 4 - metabolism Platelets Renal cell carcinoma Studies Targeted cancer therapy Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - blood |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF_k8MEXsX41teoigvoQe8nuZrOPVSwKUsWP0rdlv9I7uCZHcif43zuT7IVGCvXBp3CZSbibmZ2duZ35DSEvgxC-UAIPWY1POechVdJjF7CsMsuUnft-aslneXpanp-rr1dGfWFN2AAPPAjuSBhulHWVc3PLveBWKAdJgDTSmjxzfZvvXKpdMjX4YFjFRREb5ZjMjqJe3q6bOuDZAyTabLIR9Xj9o1eerVdNd13I-Xfl5JWt6OQeuRtjSHo8fPc9civU98leXKUdfR2hpN88IIuzWGhKQ-2x12oF5kYvIPXeLOgwaocuawoE6pati6O88JZDa2hphF3t6KX5TetmQ22ghuKgFYjA4dOyucT6nvYh-Xny4cf7j2mcrZC6QmWbtGRVbgrIpEtfWQm7tuIit7C8S4xp4CJyVUlWMe54bnwunEUwRx5KAxlbZtgjMqtBmvuEzoPMvAVPITLPK2PKEFzllQqBcaHmPiFsJ2jtIvA4zr9Y6f40TUICMshNo3p0VE9C0vGp9QC8cQP_O9ThyIuw2f0NMCYdjUnfZEwJeY4WoIce1HHx62MOWVkJwWiekBc9B0Jn1Fibc2G2Xac_fTn7B6bv3yZMryJT1YA4nIn9EPCbEJJrwnk44QQH4CbkfbTXnVQ6DSFcyRhsZQU8ubPh68l0JONLsd6uDs220-DFc4zss4Q8Hix-FGwOEbxkHAQuJ2thIvkppV4ueuBySCUgHmQH_0NVT8id4e99LNI8JLNNuw1PyW33a7Ps2me9N_gDZ71nOw priority: 102 providerName: Directory of Open Access Journals – databaseName: Nursing & Allied Health Database dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1Nb9Mw1ILCgQswvlYYYCEk4BDWxHYcn9BarYAEZSow7RY5trNWKklJWiT-Pe8lbiBoAiROkeKXKHnfz34fhDx1QthYCTxk1TbgnLtASYtVwDIPM6aykW2mlryTs1lydqZO_IZb7dMqdzqxUdS2NLhHfgh2KWEM5DN-tf4a4NQoPF31IzQukysh-sbAz3J-utPEIMtx7MvlmAwPPXVersvC4QkEhNusZ46arv2dbh6sV2V9keP5e_7kLwZpeuN_f-Umue5dUXrU8s4eueSKW2TPC3tNn_uO1C9uk8Wpz1elx4XFkq0VcC19DRH8ZkGnzcQeuiwoLNDJsjJ-IhjemiBTVfSk7d5a0_f6O52VGzp2VNM51rYDZel4WX7BNKHqDvk8Pf40eRP4EQ2BiVW4CRKWRzqGgDyxeSbB-Csuogy0RIKuEVxEpHLJcsYNj7SNhMmwJyR3iYbAL9TsLhkUQI59QkdOhjYDhSNCy3OtE-dMbpVyjnGhRnZI2I5SqfH9y3GMxiptDuUkxDEt3lKkb-rpOyRB99S67d_xF_gxMkEHi923mxtldZ56YU6F5lplJjdmlHEreCaUgcBUapnpKDTJkDxGFkrbUtZOh6RHHIK7BHzaaEieNBDYgaPAFJ9zva3r9O2H038A-jjvAT3zQHkJ6DDal1XAP2Fnrx7kQQ8S9IjpLe8jw--wUqc_2RSe3DHyxcu0W8aXYtpe4cptnYIxiDBACIfkXisyHWIjCAQk44Bw2ROmHub7K8Vy0fQ_h4gE3Ep2_89f9YBca_f_MYvzgAw21dY9JFfNt82yrh41iuIHUb5y7Q priority: 102 providerName: ProQuest |
| Title | Vascular Endothelial Growth Factor in the Circulation in Cancer Patients May Not Be a Relevant Biomarker |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21637343 https://www.proquest.com/docview/1298331536 https://www.proquest.com/docview/870293261 https://pubmed.ncbi.nlm.nih.gov/PMC3102663 https://doaj.org/article/5a4a9bcfcc0b4d54b59c1447a7ba21c8 http://dx.doi.org/10.1371/journal.pone.0019873 |
| Volume | 6 |
| WOSCitedRecordID | wos000291052200017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: PLoS Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1db9Mw0GIdD7wA42uFUSyEBDxkNLETJ49r1cK0tUQdVIOXyLEdWqkkVdMi8e-5S9xCpk3Ay0XKnaPkfD7fxfdByCvj-zqIfDxkldrhnBsnEhqzgEXmpixKu7rqWnIuxuPw8jKKfzuKV07wmXDfWZ4eL4vc4LkBOMlsj-x7LAiwVcMwPt9qXli7QWDT424a2dh-qir9O13cWi6K8jpD82q85B8b0PDe_776fXLXmpr0pJaNA3LL5A_IgV3MJX1jK06_fUhmUxuPSge5xpSsBUglfQ8e-npGh1VHHjrPKSBof75StuMX3uqj0KxoXFdnLelI_qTjYk17hko6wdx1mDnamxffMQxo9Yh8Hg4-9T84tgWDo4LIXTshyzwZgMMd6iwVsLlH3PdS0AIhmj5w8b0oEyxjXHFPas9XKdZ85CaU4Ni5kj0mrRy-_pDQrhGuTkGh-K7mmZShMSrTUWQM437U1W3CtjOTKFufHNtkLJLq0E2An1LzLUF2JpadbeLsRi3r-hx_oe_hpO9osbp2dQPmLbGLNfEll1GqMqW6Kdc-T_1IgeMppEil56qwTV6gyCR1qupORyQnHJy3EGxWr01eVhRYYSPHEJ5vclOWyenH6T8QXUwaRK8tUVYAO5S0aRPwTVi5q0F51KAEPaEa6EMU8C1XygQsvZAx2PECGLkV-uvRdIfGh2JYXm6KTZmAsvfQAXDb5Em9RHaM9cDQF4wDw0Vj8TQ438Tk81lV3xw8DjAb2dObX_gZuVP_28cIzSPSWq825jm5rX6s5-WqQ_bEZIrwUlQwBBj23Q7Z7w3G8aRT_XfpVKoD4FnvGOCoe4ZQxBW8ABj7X2FEfDqKv_wCo4Ztrg |
| linkProvider | Public Library of Science |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgAQXoLwaKHSFQMDBNPauXweEmtDSqGmoSql6M-vddRMp2MFOqPqn-I3M2GuDUQVceuBkyTu27PF8MzueFyHPtOsqL3QxyCqUxTnXVugrrAL2EztmYdxT5dSSkT8eBycn4cEK-V7XwmBaZa0TS0WtMon_yDfBLgWMAT69t_OvFk6NwuhqPUKjEos9fX4GLlvxZvgOvu9zx9nZPhrsWmaqgCW90F5YAUsc4YEPGagk9sFehdx1YhDsAK05HFwnTHyWMC65I5TjyhjbGHIdCPBVbMHgvlfIVc4chigKBk1KCegOzzPlecy3N400vJ5nqcaIB7j3rGX-yikBjS3ozGdZcdFG9_d8zV8M4M6t_411t8lNs9WmWxU2VsmKTu-QVaPMCvrSdNx-dZdMjk0-Lt1OFZakzQCV9H2enS0mdKecSESnKYUFOpjm0kw8w1MDBE1OD6rutAXdF-d0nC1oX1NBD7F2HySX9qfZF0yDyu-RT5fyxvdJJ4XPv0ZoT_u2ikGhurbiiRCB1jJRYag1427YU13CasmIpOnPjmNCZlEZdPTBT6v4FqE8RUaeusRqrppX_Un-Qt9HoWtosbt4eSLLTyOjrCJXcBHGMpGyF3Pl8tgNJTjevvBj4dgy6JINFNmoKtVtdGS0xcF5DWDP7nTJ05ICO4ykmMJ0KpZFEQ0_HP8D0cfDFtELQ5RkwA4pTNkIvBN2LmtRrrcoQU_K1vIaAqzmShH9hAVcWQPn4mXaLONNMS0x1dmyiMDYOegA2V3yoIJow1gHHB2fcWC43wJvi_PtlXQ6Kfu7g8cF22b28M9PtUGu7x7tj6LRcLz3iNyoYh2YsbpOOot8qR-Ta_LbYlrkT0olRcnny4b2DzduzO4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgBAXoLwaKHSFQMDBJPauvfYBob4CVUuIClS9mfXuuolU7GCnVP1r_Dpm7LXBqAIuPXCK5B1b8eT7Znay8yDkifF9HUQ-HrJK7XDOjRMJjVXAInUTFiVDXU0t2RPjcXh4GE2WyPemFgbTKhubWBlqnSv8j3wAfilkDPgZDFKbFjHZGr2ef3VwghSetDbjNGqI7JqzUwjfylc7W_BbP_W80fbHzbeOnTDgqCByF07IUk8GEE-GOk0E-K6I-14CIA_Rs8OH70WpYCnjintSe75KsKUhN6GEuMWVDJ57iVwWPBh6VdrgpPECYEeCwJbqMeEOLDJezvPM4OkHhPqs4wqriQGtX-jNj_PyvE3v77mbvzjD0Y3_WY03yXW7BafrNWeWyZLJbpFla-RK-tx24n5xm0wPbJ4u3c40lqodA1vpmyI_XUzpqJpURGcZhQW6OSuUnYSGlzaRTAWd1F1rS_pOntFxvqAbhkq6jzX9gGi6Mcu_YHpUcYd8upA3vkt6GUBhhdChEa5OwND6ruaplKExKtVRZAzjfjTUfcIalMTK9m3H8SHHcXUYKSB-q_UWI7Zii60-cdq75nXfkr_IbyAAW1nsOl5dyIuj2Bqx2JdcRolKlRomXPs88SMFAbmQIpGeq8I-WUP4xnUJb2s743UOQW0Ie3mvTx5XEth5JEPwHcmTsox33h_8g9CH_Y7QMyuU5qAOJW05CbwTdjTrSK52JMF-qs7yCpKt0UoZ_6QI3NmQ6Pxl2i7jQzFdMTP5SRmDE_QwMHL75F5N11axHgRAgnFQuOgQuaP57ko2m1Z93yESg-00u__nb7VGrgKj472d8e4Dcq0-AsFE1lXSWxQn5iG5or4tZmXxqLJXlHy-aGb_AKQ-1fo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vascular+Endothelial+Growth+Factor+in+the+Circulation+in+Cancer+Patients+May+Not+Be+a+Relevant+Biomarker&rft.jtitle=PloS+one&rft.au=Niers%2C+Tatjana+M.+H&rft.au=Richel%2C+Dick+J&rft.au=Meijers%2C+Joost+C.+M&rft.au=Schlingemann%2C+Reinier+O&rft.date=2011-05-26&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=6&rft.issue=5&rft.spage=e19873&rft_id=info:doi/10.1371%2Fjournal.pone.0019873&rft.externalDocID=A476889512 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |